These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Kaundal RK; Sharma SS Drug News Perspect; 2010 May; 23(4):241-56. PubMed ID: 20520853 [TBL] [Abstract][Full Text] [Related]
25. Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease. Liu ZJ; Li ZH; Liu L; Tang WX; Wang Y; Dong MR; Xiao C Front Pharmacol; 2016; 7():261. PubMed ID: 27594837 [TBL] [Abstract][Full Text] [Related]
26. Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. Fakan B; Szalardy L; Vecsei L Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669473 [TBL] [Abstract][Full Text] [Related]
27. PPAR Regulation of Inflammatory Signaling in CNS Diseases. Bright JJ; Kanakasabai S; Chearwae W; Chakraborty S PPAR Res; 2008; 2008():658520. PubMed ID: 18670616 [TBL] [Abstract][Full Text] [Related]
28. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. Jiang Q; Heneka M; Landreth GE CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811 [TBL] [Abstract][Full Text] [Related]
29. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Chen Z; Zhong C Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509 [TBL] [Abstract][Full Text] [Related]
30. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1. Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226 [TBL] [Abstract][Full Text] [Related]
31. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. Gasparini L; Ongini E; Wenk G J Neurochem; 2004 Nov; 91(3):521-36. PubMed ID: 15485484 [TBL] [Abstract][Full Text] [Related]
32. The Role of PPARs in Disease. Wagner N; Wagner KD Cells; 2020 Oct; 9(11):. PubMed ID: 33126411 [TBL] [Abstract][Full Text] [Related]
33. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Cheng Y; Dong Z; Liu S Pharmacology; 2014; 94(1-2):1-12. PubMed ID: 25171128 [TBL] [Abstract][Full Text] [Related]
40. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. Pasinetti GM J Alzheimers Dis; 2002 Oct; 4(5):435-45. PubMed ID: 12446975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]